2020 - A Year Full Of Potentials, page-185

Cutting edge-technology

Cynata’s Cymerus technology overcomes the challenges of other production methods to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Macdonald said this put Cynata ahead of the pack in terms of commercial product development.

He said: “For a small Aussie company with a hundred million or so market cap to be the leader in the world in this area - and there’s no dispute about that as for this particular type of cell therapy we are well and truly the leader as first company to complete a clinical study – it’s really a very exciting place to be.

“The technology provides a consistent manufacturing process - and that consistency and reproducibility is a vital element of successful drug product development.”

@Bazsa

I don't think you understand the difference in the cells were are developing.

You still going on about this, and your cronies still think Cynata in encroaching MSB patents which is even more laughable.

do not advertise external links.au/companies/news/912615/cynata-therapeutics-aims-for-commercial-production-of-cutting-edge-stem-cell-products-912615.html